Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Not yet recruiting 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Prolymphocytic 1

Interventions

Rituximab 193Cyclophosphamide 177fludarabine phosphate 151Peripheral Blood Stem Cell Transplantation 89fludarabine 77Mycophenolic Acid 70Filgrastim 63Whole-Body Irradiation 59Tacrolimus 55Lenalidomide 54Cyclosporine 54ibrutinib 53Bendamustine Hydrochloride 50Busulfan 49Melphalan 45Radiotherapy 42Etoposide 42Alemtuzumab 42Antilymphocyte Serum 40ofatumumab 35obinutuzumab 33Methotrexate 33venetoclax 27Cytarabine 25sargramostim 23Granulocyte Colony-Stimulating Factor 22Dexamethasone 21Methylprednisolone 19Bortezomib 19Chlorambucil 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Leukemia, Lymphocytic, Chronic, B-Cell × tafasitamab × Clear all
NCT02005289 2025-12-15

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
41 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02639910 2021-12-20

COSMOS

MorphoSys AG

Phase 2 Completed
24 enrolled 13 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01161511 2014-04-21

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Xencor, Inc.

Phase 1 Completed
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡